PDCD1 and non-small cell lung carcinoma: Anti-programmed cell death-1 (PD-1), anti-programmed cell death ligand-1 (PD-L1), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies combined with platinum-based chemotherapy have drastically improved the survival outcomes of patients with advanced non-small cell lung cancer (NSCLC) [1–6].